Editas Medicine, Inc.
EDIT· Nasdaq
EDITEditas Medicine, Inc.
Filed Feb 28, 2024 · 10-K · 59 days after period end · 0001650664-24-000008
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $60.05M | $6.54M | $12.47M | $11.42M |
| Net Income | -$18.87M | -$60.74M | -$41.44M | -$62.50M |
| EPS Diluted | — | — |
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
| — |
| -$1.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2023 · filed Feb 28, 2024 · 59 d after period end
